Skip to Content

Tema Obesity & Cardiometabolic ETF HRTS

Medalist Rating as of | See Tema Global Investment Hub

Morningstar’s Analysis HRTS

Will HRTS outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

The combination of a middling Process Pillar rating and a Below Average People Pillar rating limit Tema Obesity& Cardiometabolic ETF to a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings HRTS

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 39.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Vertex Pharmaceuticals Inc

5.39 3.3 Mil
Healthcare

Amgen Inc

5.34 3.3 Mil
Healthcare

Eli Lilly and Co

4.96 3.0 Mil
Healthcare

Novo Nordisk A/S Class B

4.70 2.9 Mil
Healthcare

DexCom Inc

4.25 2.6 Mil
Healthcare

Insulet Corp

3.07 1.9 Mil
Healthcare

Crinetics Pharmaceuticals Inc

2.96 1.8 Mil
Healthcare

Cytokinetics Inc

2.86 1.8 Mil
Healthcare

Medtronic PLC

2.83 1.7 Mil
Healthcare

Edwards Lifesciences Corp

2.80 1.7 Mil
Healthcare